Literature DB >> 25871901

Nodal Yield: Is it a Prognostic Factor for Head and Neck Squamous Cell Carcinoma?

Zhien Feng1, Li Zheng Qin2, Xin Huang3, Jin Zhong Li1, Ming Su4, Zhengxue Han5.   

Abstract

PURPOSE: The prognostic value of lymph node yield (LNY) in head and neck squamous cell carcinoma (HNSCC) remains controversial. The aim of this study was to explore whether LNY influences locoregional recurrence risk and prognosis in patients with HNSCC. PATIENTS AND METHODS: This retrospective cohort study reviewed the records of 1,546 eligible patients with HNSCC who were treated at Beijing Stomatological Hospital, Capital Medical University, from July 1989 to October 2012. The predictor variable was LNY. The main outcome assessment parameters were 2-year neck recurrence rate (NRR) and 5-year disease-specific survival (DSS). All statistical analyses were performed using SPSS 19.0 for Windows.
RESULTS: The mean and median LNY per neck dissection were 25.1 and 23.0, respectively. There was no significant association between LNY quartile and 2-year NRR in the pN0 (P = .397) or pN(+) (P = .335) group. Univariate analysis of the pN0 group showed no significant association between LNY and 5-year DSS (P = .676). The analysis of patients with pN(+) who underwent only selective neck dissection showed a significantly higher prognostic risk with an increased LNY (LNY <19 vs ≥34, 79.2% vs 59.4%; P = .014). Interestingly, in the comprehensive neck dissection subgroup, there was an obvious tendency for patients with a high LNY to have a better 5-year DSS than those with a low LNY (LNY <19 vs ≥34, 55.6% vs 76.4%; P = .021). Multivariate analysis showed that LNY was not an independent predictive factor for 2-year NRR or 5-year DSS.
CONCLUSIONS: LNY is statistically associated with the risk of lymph node metastasis, but does not predict neck recurrence. The exact prognostic value of LNY for patients with pN(+) remains unknown, and further study is needed to validate the present findings.
Copyright © 2015 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25871901     DOI: 10.1016/j.joms.2015.03.027

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  5 in total

1.  Nodal yield of neck dissections and influence on outcome in laryngectomized patients.

Authors:  Arne Böttcher; Steffen Dommerich; Steffen Sander; Heidi Olze; Carmen Stromberger; Annekatrin Coordes; Nate Jowett; Steffen Knopke
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-02-13       Impact factor: 2.503

2.  Prognostic value of the lymph node ratio in oropharyngeal carcinoma stratified for HPV-status.

Authors:  Christian Jacobi; Josepha Rauch; Jan Hagemann; Thomas Lautz; Maximilian Reiter; Philipp Baumeister
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-04       Impact factor: 2.503

3.  Preoperative SCC Antigen, CRP Serum Levels, and Lymph Node Density in Oral Squamous Cell Carcinoma.

Authors:  Mohamad Adel; Chung-Kan Tsao; Fu-Chan Wei; Huei-Tzu Chien; Chih-Hsiung Lai; Chun-Ta Liao; Hung-Ming Wang; Kang-Hsing Fan; Chung-Jan Kang; Joseph Tung-Chieh Chang; Shiang-Fu Huang
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

4.  Intraoperative Brief Electrical Stimulation of the Spinal Accessory Nerve (BEST SPIN) for prevention of shoulder dysfunction after oncologic neck dissection: a double-blinded, randomized controlled trial.

Authors:  Brittany Barber; Hadi Seikaly; K Ming Chan; Rhys Beaudry; Shannon Rychlik; Jaret Olson; Matthew Curran; Peter Dziegielewski; Vincent Biron; Jeffrey Harris; Margaret McNeely; Daniel O'Connell
Journal:  J Otolaryngol Head Neck Surg       Date:  2018-01-23

5.  Lymph node ratio is associated with adverse clinicopathological features and is a crucial nodal parameter for oral and oropharyngeal cancer.

Authors:  Zhien Feng; Qiao Shi Xu; Chong Wang; Jin Zhong Li; Ming Hui Mao; Hua Li; Li Zheng Qin; Zhengxue Han
Journal:  Sci Rep       Date:  2017-07-27       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.